Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 22

1.

Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.

Lebois EP, Bridges TM, Lewis LM, Dawson ES, Kane AS, Xiang Z, Jadhav SB, Yin H, Kennedy JP, Meiler J, Niswender CM, Jones CK, Conn PJ, Weaver CD, Lindsley CW.

ACS Chem Neurosci. 2010;1(2):104-121.

2.

Chemical lead optimization of a pan G(q) mAChR M(1), M(3), M(5) positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M(5) PAM.

Bridges TM, Kennedy JP, Cho HP, Breininger ML, Gentry PR, Hopkins CR, Conn PJ, Lindsley CW.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):558-62. doi: 10.1016/j.bmcl.2009.11.089. Epub 2009 Nov 22.

3.

Parallel synthesis of N-biaryl quinolone carboxylic acids as selective M(1) positive allosteric modulators.

Yang FV, Shipe WD, Bunda JL, Nolt MB, Wisnoski DD, Zhao Z, Barrow JC, Ray WJ, Ma L, Wittmann M, Seager MA, Koeplinger KA, Hartman GD, Lindsley CW.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):531-6. doi: 10.1016/j.bmcl.2009.11.100. Epub 2009 Nov 24.

PMID:
20004574
4.

A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning.

Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, Jadhav SB, Menon UN, Xiang Z, Watson ML, Christian EP, Doherty JJ, Quirk MC, Snyder DH, Lah JJ, Levey AI, Nicolle MM, Lindsley CW, Conn PJ.

J Neurosci. 2009 Nov 11;29(45):14271-86. doi: 10.1523/JNEUROSCI.3930-09.2009.

5.

Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation.

Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M, Jones K, Graufelds VK, Xu G, Pearson M, McCampbell A, Gaspar R, Shughrue P, Danziger A, Regan C, Flick R, Pascarella D, Garson S, Doran S, Kreatsoulas C, Veng L, Lindsley CW, Shipe W, Kuduk S, Sur C, Kinney G, Seabrook GR, Ray WJ.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15950-5. doi: 10.1073/pnas.0900903106. Epub 2009 Aug 26. Erratum in: Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):18040. Seager, Matthew [corrected to Seager, Matthew A].

6.

Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins.

Bridges TM, Marlo JE, Niswender CM, Jones CK, Jadhav SB, Gentry PR, Plumley HC, Weaver CD, Conn PJ, Lindsley CW.

J Med Chem. 2009 Jun 11;52(11):3445-8. doi: 10.1021/jm900286j.

7.

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.

Conn PJ, Christopoulos A, Lindsley CW.

Nat Rev Drug Discov. 2009 Jan;8(1):41-54. doi: 10.1038/nrd2760. Review.

8.

Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity.

Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, Rodriguez AL, Shirey JK, Brady AE, Nalywajko T, Luo Q, Austin CA, Williams MB, Kim K, Williams R, Orton D, Brown HA, Lindsley CW, Weaver CD, Conn PJ.

Mol Pharmacol. 2009 Mar;75(3):577-88. doi: 10.1124/mol.108.052886. Epub 2008 Dec 1.

9.

Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.

Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ.

J Neurosci. 2008 Oct 8;28(41):10422-33. doi: 10.1523/JNEUROSCI.1850-08.2008.

10.

Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats.

Brady AE, Jones CK, Bridges TM, Kennedy JP, Thompson AD, Heiman JU, Breininger ML, Gentry PR, Yin H, Jadhav SB, Shirey JK, Conn PJ, Lindsley CW.

J Pharmacol Exp Ther. 2008 Dec;327(3):941-53. doi: 10.1124/jpet.108.140350. Epub 2008 Sep 4.

11.

G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms.

Bridges TM, Lindsley CW.

ACS Chem Biol. 2008 Sep 19;3(9):530-41. doi: 10.1021/cb800116f. Epub 2008 Jul 25. Review.

PMID:
18652471
12.

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC.

Am J Psychiatry. 2008 Aug;165(8):1033-9. doi: 10.1176/appi.ajp.2008.06091591. Epub 2008 Jul 1.

PMID:
18593778
13.

M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors.

Fisher A.

Neurodegener Dis. 2008;5(3-4):237-40. doi: 10.1159/000113712. Epub 2008 Mar 6. Review.

PMID:
18322400
14.

Muscarinic acetylcholine receptors as CNS drug targets.

Langmead CJ, Watson J, Reavill C.

Pharmacol Ther. 2008 Feb;117(2):232-43. Epub 2007 Dec 20. Review.

PMID:
18082893
15.

M1 receptors play a central role in modulating AD-like pathology in transgenic mice.

Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM.

Neuron. 2006 Mar 2;49(5):671-82.

16.

Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications.

Wess J.

Annu Rev Pharmacol Toxicol. 2004;44:423-50. Review.

PMID:
14744253
17.

Discovery of an ectopic activation site on the M(1) muscarinic receptor.

Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR.

Mol Pharmacol. 2002 Jun;61(6):1297-302.

18.

Therapeutic opportunities for muscarinic receptors in the central nervous system.

Felder CC, Bymaster FP, Ward J, DeLapp N.

J Med Chem. 2000 Nov 16;43(23):4333-53. Review. No abstract available.

PMID:
11087557
19.

Muscarinic receptor ligands and their therapeutic potential.

Eglen RM, Choppin A, Dillon MP, Hegde S.

Curr Opin Chem Biol. 1999 Aug;3(4):426-32. Review.

PMID:
10419852
20.

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM.

Arch Neurol. 1997 Apr;54(4):465-73.

PMID:
9109749

Supplemental Content

Support Center